A number of appeals were made against the Institute's Final Appraisal Determination on the use of rituximab for follicular lymphoma. Elements of the appeals were upheld. The full text of the appeal is published on the website and can be accessed by clicking on the link below. The Institute's Appraisal Committee will be asked to review its determination in the light of the Appeal Panel's decision and recommendations.
The Institue's Appraisal Committee reviewed its determination in light of the Appeal Panel's decision and recommendation at its meeting in September and November 2001. A new final appraisal determination will be prepared and circulated to consultees for appeal.